XML 86 R55.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Disclosures - Schedule of Significant Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:    
Non-cash stock compensation $ 2,042 $ 2,750
Total operating expenses 26,825 23,881
Loss from operations (26,825) (23,881)
Interest Income 183 1,187
Change in fair value of the tranche rights 0 4,796
Other income (expense) 1,169 (2,094)
Net loss (25,473) (29,584)
Reportable Segment    
Operating expenses:    
Clinical product candidates 17,781 14,952
Pre-clinical product candidates 114 181
Non-cash stock compensation 2,042 2,741
Depreciation expense 43 26
Professional fees and other segment expenses 3,118 2,622
Total operating expenses 26,825 23,881
Loss from operations (26,825) (23,881)
Interest Income 183 1,187
Change in fair value of the tranche rights 0 4,796
Other income (expense) 1,169 (2,094)
Net loss (25,473) (29,584)
Reportable Segment | Research and development    
Operating expenses:    
Employee costs 2,167 2,002
Reportable Segment | General and administrative    
Operating expenses:    
Employee costs $ 1,560 $ 1,357